Table 3.
Factors Associated with Mortality
| Survivors N (%) |
Non-survivors N (%) |
Univariate | Univariate | Multivariable | ||
|---|---|---|---|---|---|---|
| Demographic Characteristic | (N=18) | (N=17) | Odds Ratio (95% CI) | P value | Odds Ratio (95% CI) | P value |
| Age, mean years (SD) | 42.8 (±14.5) | 42.2 (±13.5) | 0.947 | |||
| Recipient CMV seropositivity | 15 (83.3%) | 14 (82.4%) | 0.933 (0.161–5.42) | 0.642 | ||
| HLA matched | 12 (66.7%) | 12 (70.6%) | 1.2 (0.287–5.02) | 0.546 | ||
| Unrelated donor | 9 (50%) | 12 (70.6%) | 2.4 (0.596–9.67) | 0.305 | ||
| Max CMV PCR titer, median copies/mL (range)a | 38,840 (2000–730,000) | 217,350 (48,600–4.6*106) | 0.099 | |||
| Charlson Comorbidity Index, median (range) | 2 (2–4) | 3 (2–5) | 0.069 | |||
| Graft versus host disease | 16 (88.9%) | 9 (52.9%) | 0.141 (0.0244–0.811) | 0.027 | ||
| Intubation required due to CMV pneumonitisb | 3 (25%) | 11 (78.6%) | 11.0 (1.77–68.4) | 0.016 | 12.2 (1.09–138) | 0.042 |
| CMV disease diagnosis, median days post-HSCT (range) | 106 (20–369) | 48 (0–90) | <0.001 | 0.959 (0.916–1.004) | 0.075 |
SD – Standard deviation; CMV – Cytomegalovirus; HLA – Human leukocyte antigen; PCR – Polymerase chain reaction; HSCT – Hematopoietic stem cell transplant; CI –Confidence interval
a
Survivors (N=9) and non-survivors (N=6), as this testing method was not available for the full cohort
b
Survivors (N=12) and non-survivors (N=14), as only 26 patients had CMV pneumonitis